Blog Posts
February 26, 2024

From Passion to Profession: Meet LARVOL’s VP Sales, Linh Nguyen

Blog Posts
February 26, 2024

From Passion to Profession: Meet LARVOL’s VP Sales, Linh Nguyen

Author
Neneh Vannitamby, MD
Medical Writer

In this edition of our ongoing series "In The Spotlight", we're excited to chat with Linh Nguyen, the VP Sales at LARVOL. With a passion for healthcare and a commitment to making a difference in the oncology field, Linh has been a vital part of our team for over six years. Let’s get to know Linh better through her own words, exploring her journey, motivations, and the personal interests that round out her life.

Linh Nguyen, VP Sales

1. Could you briefly introduce yourself and describe your role at LARVOL?

I'm Linh Nguyen and I lead the Sales team here at LARVOL. My role is all about building strong relationships with our pharma and biotech customers, ensuring they have the cancer data they need to make informed decisions. It's been a rewarding six years, helping our customers navigate the complexities of oncology data to support their vital work.

 

2. Every person's journey is unique. Can you share with us how you landed in the field of oncology and at LARVOL specifically?

 

My journey into oncology was sparked by a genuine interest in healthcare, especially in understanding and combating cancer. My involvement in a research project on breast cancer during my final year of university deepened my interest in oncology and led me to seek a career where I could blend my passion for healthcare with innovative technology. The opportunity at LARVOL presented itself as a perfect blend of these interests, thanks to connecting online with Bruno, LARVOL's founder.

 

3. What do you enjoy most about your role at LARVOL and how has it impacted your professional journey?

 

This role has been the most fulfilling one in my career so far. I find immense joy in solving problems, ensuring everything runs smoothly, and fitting together the pieces of a complex puzzle. Challenges are inevitable, but they're also opportunities for growth and improvement. Overcoming them is a part of the job I genuinely enjoy.

 

4. In an industry as fast-paced as ours, it's important to have strong motivation. What personally motivates you in your role at LARVOL and how do you keep that motivation alive in the face of challenges?

 

Knowing that our work eventually contributes to improving patient outcomes is a powerful motivator. While we don't interact with patients directly, the thought that our efforts can make a difference in their lives keeps me focused and driven. Additionally, the collective motivation and dedication of my colleagues at LARVOL inspires me to push forward, even when obstacles arise.

 

5. At LARVOL, we know the importance of work-life balance. Outside of your professional role, what unique hobby or interest might surprise your colleagues at LARVOL?

 

Away from the office, I cherish my time with my dog and loved ones. Cooking and baking are my go-to activities for relaxation. They allow me to express creativity and share something tangible and enjoyable with my family and friends.

 

Through Linh's story, we glimpse the dedication and passion that drive our team at LARVOL. Stay tuned for more inspiring stories from our talented team members in future editions of our "In the Spotlight” series.

Download attached file
Not rated
Allison Betof Warner, MD, PhD (she/her) 4
3743
Manhattan, NY
November 10, 2022

79% had reduction in disease. ORR 31%. Many responses deepen over time.

Not rated
Allison Betof Warner, MD, PhD (she/her) 3
3743
Manhattan, NY
November 10, 2022

Median DOR not yet reached. Median OS 13.9 mo. 12 mo OS was 54%. As typical with immunotherapy, we see a nice tail on the curve. #TIL#SITC22

Positive
Alex Shoushtari, MD
2253
New York, USA
November 10, 2022

Important work on efficacy of TIL therapy lifileucel in PD-1 resistant #melanoma being presented at #SITC22. Pretty good durability for this heavy lift of a treatment.

Not rated
Allison Betof Warner, MD, PhD (she/her) 2
3743
Manhattan, NY
November 10, 2022

Toxicity profile was in line with prior TIL/Lifileucel data. No surprises here. Median # doses of IL-2 was 6.

Positive
Hussein Tawbi, MD, PhD
1685
Houston, TX
November 10, 2022

Absolutely agree!… this should be available to our melanoma patients ASAP!… and paves the way for smarter cellular therapies to be designed, studied, and eventually widely disseminated

Positive
Allison Betof Warner, MD, PhD (she/her) 1
3744
Manhattan, NY
November 10, 2022

Where does this leave us with #TIL therapy for #melanoma? IMO, this response rate/durability justifies accelerated approval. Pts with PD-1 refractory melanoma need options. It’s FAR from a perfect tx but provides meaningful clinical benefit. What say you melanoma Twitterverse?

Not Rated
Sumanta K. Pal, MD, FASCO
15083 Followers
Los Angeles, CA
November 8, 2022

Just before I start AM clinic at @cityofhopeoc, excited to share results from #COBALT_RCC, a P1 trial of @CRISPRTX#CTX130 in #kidneycancer in the @sitcancer#PressProgram. Will present more on Thurs 5:37p at #SITC22! Thx @neerajaiims@DrBenTran@HaanenJohn#SamerSrour& co-Is! t.co/aDnhG9n92A

not rated
Shilpa Gupta
5095 Followers
Cleveland, OH
November 8, 2022
Not Rated
Tian Zhang, MD, MHS
6463 Followers
Dallas, TX
November 8, 2022

CAR-Ts are coming for #kidneycancer!! Congratulations @montypal and team; can’t wait to see results at #SITC22! t.co/9MrlF2yzBe

Not Rated
Moshe Ornstein MD
1930 Followers
Cleveland, OH
November 8, 2022

Congrats @montypal and team! Great to see CAR T therapy coming to #RCCt.co/ypRHBC89Pt

Not Rated
Shuchi Gulati MD
12476 Followers
Seattle, WA
November 8, 2022

Another huge step from none other than @montypal!! CAR-Ts in #kidneycancer!Congratulations to the entire team!Looking forward to seeing the results at #SITC22! t.co/HvKeVBPyV7

Not Rated
Petros Grivas
12476 Followers
Seattle, WA
November 8, 2022

Subscribe to our newsletter

Sign up for our newsletter to get the latest news, updates and high-impact data delivered directly to your inbox.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.